Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-EGFR] after 182-hours was consistently greater than epirubicin-(C3-amide)-[anti-HER2/neu] following a 96-hour incubation period against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) at and between chemotherapeutic-equivalent concentrations of 10−13 M and 10−7 M (Figure. The gene discussed is ERBB2; the disease is breast adenocarcinoma.